Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20750900 | 0.92 | CNR1 (0.51) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL14748061 | 0.91 | GLP1R (0.61) | GLP1RFAAHENPP2LPAR1LPAR2 | |
| SCHEMBL14748065 | 0.91 | GLP1R (0.61) | GLP1RFAAHENPP2LPAR1LPAR2 | |
| SCHEMBL14728241 | 0.91 | GLP1R (0.61) | GLP1RFAAHENPP2LPAR1LPAR2 | |
| SCHEMBL24950256 | 0.91 | CNR1 (0.57) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL13566316 | 0.91 | CNR1 (0.57) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL14438836 | 0.91 | CNR1 (0.57) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL19389411 | 0.91 | CNR1 (0.57) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL14438834 | 0.91 | CNR1 (0.57) | CNR1GLP1RFAAHENPP2LPAR1 | |
| SCHEMBL13640974 | 0.90 | FAAH (0.62) | GLP1RFAAHENPP2LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | CNR1 1239/4885GLP1R 1/4885FAAH 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.